clinical trial · NCT05191706
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
EyePoint Pharmaceuticals, Inc.·phase4·recruiting·n = 60
CataractDexamethasonePrednisolone Acetate Ophthalmic
brief summary
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
started
Jan 4, 2022
primary completion
Jan 1, 2026
completion
Feb 1, 2026
last updated
Apr 3, 2025
official title
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol